Preferred Label : mirikizumab;

MeSH hyponym : LY3074828;

UNII : Z7HVY03PHP;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.has-sante.fr/jcms/p_3497164/fr/omvoh-mirikizumab-rectocolite-hemorragique
2024
false
false
false
France
mirikizumab
treatment outcome
insurance, health, reimbursement
adult
gastrointestinal agents
infusions, intravenous
injections, subcutaneous
Interleukin Inhibitors
Interleukin-23
evaluation of the transparency committee
colitis, ulcerative
mirikizumab

---
https://www.has-sante.fr/jcms/p_3539081/fr/omvoh-mirikizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
mirikizumab
injections, subcutaneous
biological therapy

---
https://www.cadth.ca/fr/mirikizumab
2023
false
false
false
Canada
French
canada
mirikizumab
drug evaluation
mirikizumab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
mirikizumab
mirikizumab
drug approval
europe
adult
colitis, ulcerative
injections, subcutaneous
infusions, intravenous
Interleukin-23
product surveillance, postmarketing
aged
pregnancy
breast feeding
mirikizumab
drug evaluation, preclinical
Interleukin Inhibitors
Interleukin Inhibitors

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.